[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015. 65(1): 5-29.
[2] Moore K, Brewer MA. Endometrial Cancer: Is This a New Disease. Am Soc Clin Oncol Educ Book. 2017. 37: 435-442.
[3] Njoku K, Chiasserini D, Whetton AD, Crosbie EJ. Proteomic Biomarkers for the Detection of Endometrial Cancer. Cancers (Basel). 2019. 11(10).
[4] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013. 19(11): 1423-37.
[5] Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015. 125(9): 3335-7.
[6] Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The Emerging Role of the Microenvironment in Endometrial Cancer. Cancers (Basel). 2018. 10(11).
[7] Felix AS, Weissfeld J, Edwards R, Linkov F. Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol. 2010. 31(2): 139-44.
[8] Pasanen A, Ahvenainen T, Pellinen T, Vahteristo P, Loukovaara M, Bützow R. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups. Am J Surg Pathol. 2020. 44(2): 174-181.
[9] Wang Z, Zhu J, Liu Y, et al. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med. 2020. 18(1): 67.
[10] Zeng Q, Zhang W, Li X, Lai J, Li Z. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value. Life Sci. 2020. 243: 117273.
[11] Zhang C, Zheng JH, Lin ZH, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020. 12.
[12] Chakraborty H, Hossain A. R package to estimate intracluster correlation coefficient with confidence interval for binary data. Comput Methods Programs Biomed. 2018. 155: 85-92.
[13] Bandettini WP, Kellman P, Mancini C, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012. 14: 83.
[14] Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018. 74(6): 756-763.
[15] Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008. 26(8): 1364-70.
[16] Zhu X, Tian X, Yu C, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016. 15(1): 60.
[17] Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018. 1711: 243-259.
[18] Charoentong P, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017. 18(1): 248-262.
[19] He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018. 37(1): 327.
[20] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013. 4: 2612.
[21] Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018. 28(11): 1747-1756.
[22] Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017. 548(7667): 297-303.
[23] Lim S, Phillips JB, Madeira da Silva L, et al. Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res. 2017. 77(6): 1245-1249.
[24] Nakazawa Y. [Chimeric antigen receptor T-cell therapy for hematological malignancies]. Rinsho Ketsueki. 2019. 60(9): 1351-1357.
[25] Rodríguez-Cerdeira C, Carnero Gregorio M, López-Barcenas A, et al. Advances in Immunotherapy for Melanoma: A Comprehensive Review. Mediators Inflamm. 2017. 2017: 3264217.
[26] Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. Cancer Treat Rev. 2017. 59: 109-116.
[27] Agrawal U, Kumari N, Mishra AK, et al. Immune signature of urothelial cancer associated with grade, recurrence, and invasion. Urol Oncol. 2016. 34(9): 418.e17-26.
[28] Jones NL, Xiu J, Rocconi RP, Herzog TJ, Winer IS. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. Gynecol Oncol. 2020. 156(2): 393-399.
[29] Liao S, Yang Y, Chen S, et al. IL-24 inhibits endometrial cancer cell proliferation by promoting apoptosis through the mitochondrial intrinsic signaling pathway. Biomed Pharmacother. 2020. 124: 109831.
[30] Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014. 192(12): 5451-8.
[31] Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017. 16(12): 1347-1357.
[32] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017. 541(7637): 321-330.
[33] Zhong C, Gragert L, Maiers M, et al. The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population. Leuk Lymphoma. 2019. 60(12): 2899-2908.
[34] Antony F, Deantonio C, Cotella D, et al. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology. 2019. 8(9): e1614856.
[35] Sasawatari S, Okamoto Y, Kumanogoh A, Toyofuku T. Blockade of N-Glycosylation Promotes Antitumor Immune Response of T Cells. J Immunol. 2020. 204(5): 1373-1385.
[36] Johnson DB, Nixon MJ, Wang Y, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 2018. 3(24).
[37] Feng Y, Pan L, Zhang B, Huang H, Ma H. BATF acts as an oncogene in non-small cell lung cancer. Oncol Lett. 2020. 19(1): 205-210.
[38] Wei J, Long L, Zheng W, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019. 576(7787): 471-476.
[39] Zhang Y, Manjunath M, Yan J, et al. The Cancer-Associated Genetic Variant Rs3903072 Modulates Immune Cells in the Tumor Microenvironment. Front Genet. 2019. 10: 754.
[40] Li X, Zhang Y, Ma W, et al. Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma. Cancer Immunol Immunother. 2020 .
[41] Ma K, Li X, Lv J, et al. Correlations between CD4+ FoxP3+ Treg and expression of FoxM1 and Ki-67 in gastric cancer patients. Asia Pac J Clin Oncol. 2020 .
[42] Strefford JC, Lane TM, Hill A, et al. Molecular characterisation of the t(1;15)(p22;q22) translocation in the prostate cancer cell line LNCaP. Cytogenet Genome Res. 2006. 112(1-2): 45-52.
[43] Li W, Bai X, Li J, et al. The nucleoskeleton protein IFFO1 immobilizes broken DNA and suppresses chromosome translocation during tumorigenesis. Nat Cell Biol. 2019. 21(10): 1273-1285.
[44] Spinner CA, Lamsoul I, Métais A, Febrissy C, Moog-Lutz C, Lutz PG. The E3 Ubiquitin Ligase Asb2α in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer. Cancer Immunol Res. 2019. 7(8): 1332-1344.
[45] Bellone S, Tassi R, Betti M, et al. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer. 2013. 109(2): 462-71.
[46] Paul S, Chhatar S, Mishra A, Lal G. Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor. J Immunother Cancer. 2019. 7(1): 208.
[47] Gorini F, Azzimonti L, Delfanti G, et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood. 2017. 129(26): 3440-3451.
[48] Hu J, Sun J. MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment. Oncoimmunology. 2018. 7(10): e1487914.
[49] Vagios S, Yiannou P, Giannikaki E, et al. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas. Int J Clin Oncol. 2019. 24(11): 1419-1428.
[50] Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol. 2019. 32(3): 396-404.
[51] Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther. 2014. 14(7): 931-45.
[52] Wang R, Feng W, Wang H, et al. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model. Cancer Lett. 2020. 469: 151-161.
[53] Deniger DC, Maiti SN, Mi T, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014. 20(22): 5708-19.
[54] Paul S, Lal G. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer. Int J Cancer. 2016. 139(5): 976-85.
[55] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015. 372(26): 2509-20.
[56] Roerden M, Nelde A, Walz JS. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy. Front Immunol. 2019. 10: 3004.
[57] Wang M, Fan W, Ye M, et al. Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. Sci Rep. 2018. 8(1): 8990.
[58] Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019. 7(10): 1570-1573.
[59] Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013. 497(7447): 67-73.
[60] Pulido R, Mingo J, Gaafar A, et al. Precise Immunodetection of PTEN Protein in Human Neoplasia. Cold Spring Harb Perspect Med. 2019. 9(12).
[61] Myers AP, Filiaci VL, Zhang Y, et al. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016. 141(1): 43-8.
[62] Zhang M, Yang D, Gold B. Origin of mutations in genes associated with human glioblastoma multiform cancer: random polymerase errors versus deamination. Heliyon. 2019. 5(3): e01265.